Malnutrition and Nutritional Deficiencies Associated with Weight Loss Therapies

Micronutrient Deficiencies
Lower levels of micronutrients are often associated with obesity and may worsen with weight loss. These include:
- Vitamins C, D, E, selenium, folate, and carotenoids
- Vitamin A, thiamine, folate, vitamin B12, vitamin D, iron, calcium, and magnesium, particularly after very low-calorie diets or bariatric surgery

Loss of Lean Body Mass and Changes in Body Composition Occur with Rapid Weight Loss
For those undergoing bariatric surgery:
- 55% of lean body mass (LBM) loss occurs within the first 3 months of surgery
- Typically, greater than 8 kg of fat-free mass (FFM) is lost within the first year of surgery
- Reduced intake of dietary protein occurs
- Unused muscle tissue is broken down to meet protein requirements
- The predictive score for sarcopenia increases from 8% to 32% within 1 year
- The gastric banding procedure produces less LBM and FFM loss, but also less weight loss in general

For those on Hormonal Incretin Therapy (GLP-1, GIP)
- Medications include Liraglutide (GLP1-RA), Semaglutide (GLP1-RA), and Tirzepatide (GLP1-RA/GIP)
- In the medication studies conducted, LBM loss ranged from 0–40% of total weight loss
- Review of studies on body composition after hormonal incretin therapy have limitations. See Table 1 for details

Strategies to Mitigate Negative Nutritional Issues

Energy
- 1200–1500 kcals/d for women, 1500–1800 kcals/day for men

Protein
- New meta-analysis indicates that intake above 1.3 g/kg/d of protein is associated with increased muscle mass, and less than 1.0 g/kg/d is associated with muscle mass decline
- Sedentary individuals should consume 1.0–1.2 g/kg/d of protein; those who exercise, up to 1.5 g/kg/d
- Divide protein amount across the 3 main meals
- Choose high-quality protein sources
- Consume high-protein foods first; meal replacement products such as shakes (15–25 g protein), bars or other formulated foods can be used to supplement dietary intake of protein

Fluids
- >2–3 L/d such as water, low-calorie beverages (unsweetened coffee or tea), or nutrient-dense beverages (low-fat, dairy or soy alternatives)

Dietary fiber
- >21 g/d for women, >30 g/d for men; good sources include fruits, vegetables, and whole grains
- Consider use of a fiber supplement—soluble, nonfermentable, gel-forming fibers such as psyllium and insoluble fibers (coarse wheat bran) can increase stool water content and bulk, which may aid stool passage

Micronutrients
- Treat preexisting deficiencies and counsel on adequate micronutrient intake
- Increase intake of food sources with micronutrients of concern such as vegetables, fruits, low-fat dairy, and fortified soy alternatives
- Consider supplementation with a complete multivitamin, vitamin D, and calcium to help reduce risk of deficiencies

Exercise and Activity
- Reduce sedentary time
- Type of exercise is important; resistance training for preserving muscle mass and strength at least 2x/week

Registered Dietitian
- Consult with a registered dietitian for patient education and support

With the current obesity epidemic and the increased use of medical and surgical treatments for weight loss, there is a growing concern about malnutrition in these patients as they lose weight. This resource highlights the nutritional issues associated with weight loss therapies and offers strategies to help prevent malnutrition during the weight loss process.
Table 1. Selected Studies on Hormonal Incretin Therapy (GLP-1, GIP) and Impact on Body Composition

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Drug</th>
<th>Duration/Number of Subjects</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jendle (2009)</td>
<td>Liraglutide SQ vs. placebo vs. Glimperide</td>
<td>26 weeks and 52 weeks / n=160</td>
<td>Liraglutide treatment reduced fat mass more than lean tissue mass while glimepiride increased the mass of one or both tissue types.</td>
</tr>
<tr>
<td>McCormimmon (2020)</td>
<td>Semaglutide SQ vs. placebo vs. canagliflozin</td>
<td>52 weeks / n=178</td>
<td>Changes in body composition between semaglutide and canagliflozin were not significantly different in participants with uncontrolled type 2 diabetes on stable-dose metformin therapy. Numerical improvements in body composition were observed following treatment in both treatment arms, the specific impact of both treatments on body composition in the absence of a placebo arm is speculative.</td>
</tr>
<tr>
<td>Wilding (2021)</td>
<td>Semaglutide SQ vs. placebo</td>
<td>68 weeks / n=1961</td>
<td>Semaglutide led to greater reduction in fat mass than lean body mass. Total lean body mass decreased in absolute terms (kg), however the proportion of lean body mass relative to total body mass increased with semaglutide.</td>
</tr>
<tr>
<td>Ozeki (2022)</td>
<td>Semaglutide SQ</td>
<td>3 months / n=48</td>
<td>Muscle mass (MM) was conserved. Although skeletal MM decreased, skeletal MM % after 3 months of semaglutide treatment was maintained. There were no changes in the upper and lower leg MM percentages or in the ratio of lower/upper MM after 3 months of semaglutide treatment.</td>
</tr>
<tr>
<td>Volpe (2022)</td>
<td>Semaglutide SQ</td>
<td>26 weeks / n=48</td>
<td>Semaglutide provided significant weight loss, predominantly due to a reduction in fat mass and visceral adipose tissue (VAT) with a mild decline in the fat-free mass index (FFMI) and skeletal muscle mass (SMM) not associated with a loss of muscle strength. The concomitant reduction in lean mass (LM) and SMM was expected, however it was considered to be clinically irrelevant.</td>
</tr>
<tr>
<td>Jastreboff (2022)</td>
<td>Weekly tirzepatide vs. placebo included a 20-week dose-escalation period</td>
<td>72 weeks / n=2539</td>
<td>Approximately three-fold greater fat mass loss than lean mass, resulting in an overall improvement in body composition. The ratio of fat-mass loss to lean-mass loss was similar to that reported with lifestyle-based and surgical treatments for obesity.</td>
</tr>
<tr>
<td>Heise (2023)</td>
<td>Tirzepatide vs. Semaglutide vs. placebo</td>
<td>28 weeks / n=117</td>
<td>Both drugs decreased weight primarily through a reduction in fat mass. Greater effects of tirzepatide than semaglutide on total body mass and fat mass reduction in people with type 2 diabetes. Total lean mass loss not reported.</td>
</tr>
</tbody>
</table>

References

Note: This content has been developed for use by healthcare professionals to inform other clinicians and/or patients/caregivers. ASIEN is making this content available for informational purposes only. This content is not based on ASPEN Board Approved documents and should not be confused with ASPEN clinical guidelines as it was not developed according to ASPEN guideline processes. Recommendations provided here do not constitute medical or other professional advice and should not be taken as such. To the extent that the information here may be used to assist in the care of patients, the primary component of quality medical care is the result of the professional judgment of the healthcare professionals providing care. The information presented here is not a substitute for the exercise of professional judgment by healthcare professionals. Circumstances and patient specifics in clinical settings may require actions different from those recommended in this document; in those cases, the judgment of the treating professional should prevail. Use of this information does not in any way guarantee any specific benefit in outcome or survival. This tool is intended to supplement, but not replace, professional training and judgment.